Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDLNASDAQ:GOVXNASDAQ:VUZI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$0.96+6.8%$1.11$0.77▼$3.12$79.06M1384,420 shs75,101 shsGOVXGeoVax Labs$1.02+7.3%$1.44$0.88▼$11.18$14.12M3.7592,518 shs648,531 shsVUZIVuzix$1.67-1.2%$2.76$0.83▼$5.79$127.32M1.721.46 million shs589,676 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics+6.81%+18.15%-14.55%-25.23%-48.82%GOVXGeoVax Labs+7.31%0.00%-38.18%-54.26%-45.74%VUZIVuzix-1.18%-1.18%-27.07%-51.03%+19.29%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics1.6919 of 5 stars3.62.00.00.02.30.00.6GOVXGeoVax Labs3.101 of 5 stars3.64.00.00.02.51.71.3VUZIVuzix0.7037 of 5 stars2.51.00.00.02.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.29Buy$8.40777.74% UpsideGOVXGeoVax Labs 3.29Buy$14.201,292.16% UpsideVUZIVuzix 3.00Buy$2.0019.76% UpsideCurrent Analyst Ratings BreakdownLatest VUZI, GOVX, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/28/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.002/27/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.002/24/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.001/31/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.001/28/2025CRDLCardiol TherapeuticsRODMAN&RENSHAWSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/28/2025CRDLCardiol TherapeuticsRodman & RenshawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$7.001/16/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 4/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AGOVXGeoVax Labs$3.95M3.57N/AN/A$3.24 per share0.31VUZIVuzix$5.75M22.13N/AN/A$1.25 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$20.84M-$0.37N/AN/AN/AN/A-194.40%-129.07%5/13/2025 (Estimated)GOVXGeoVax Labs-$25.97M-$5.67N/AN/AN/AN/A-809.87%-349.34%5/13/2025 (Estimated)VUZIVuzix-$50.15M-$1.08N/A∞N/A-1,437.17%-139.39%-131.18%5/7/2025 (Estimated)Latest VUZI, GOVX, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/A3/27/2025Q4 2024GOVXGeoVax Labs-$0.79-$0.30+$0.49-$0.30$2.38 million$3.00 million3/13/2025Q4 2024VUZIVuzix-$0.12-$0.16-$0.04-$0.16$1.53 million$1.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/AVUZIVuzixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.012.492.49GOVXGeoVax LabsN/A4.174.17VUZIVuzixN/A13.168.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%GOVXGeoVax Labs6.09%VUZIVuzix35.87%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%GOVXGeoVax Labs5.70%VUZIVuzix8.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.61 million78.27 millionNot OptionableGOVXGeoVax Labs1013.84 million8.90 millionNot OptionableVUZIVuzix11076.24 million67.51 millionOptionableVUZI, GOVX, and CRDL HeadlinesRecent News About These CompaniesVuzix Z100 Smart Glasses ReviewApril 12 at 5:13 AM | pcmag.comVuzix Z100 Smart GlassesApril 11 at 2:11 PM | au.pcmag.comVuzix Secures $500K Smart Glasses Re-Order from Augmex for European Supply Chain UseApril 7, 2025 | auganix.orgVuzix receives $500K smart glasses reorder from AugmexApril 2, 2025 | markets.businessinsider.comVuzix Bags $500K Order For Its Smart Glasses From Augmex: Retail Turns Bullish Despite Stock DeclineApril 2, 2025 | msn.comVuzix Receives $500K Smart Glasses Reorder from Augmex to Support Increasing Customer DeploymentsApril 1, 2025 | prnewswire.comVuzix Corporation (VUZI) Among Best AI Penny Stocks to Buy According to This IndicatorMarch 26, 2025 | msn.comVuzix (NASDAQ:VUZI) Shares Pass Below 200-Day Moving Average - Here's What HappenedMarch 21, 2025 | marketbeat.comVuzix announces follow-on six-figure smart glasses order from QUADMarch 19, 2025 | msn.comQUAD GmbH Expands Its Technology Offerings and Relationship with Vuzix with Follow-on Six-figure Smart Glasses OrderMarch 19, 2025 | prnewswire.comWill Vuzix (NASDAQ:VUZI) Spend Its Cash Wisely?March 15, 2025 | finance.yahoo.comVuzix Corporation (NASDAQ:VUZI) Q4 2024 Earnings Call TranscriptMarch 15, 2025 | msn.comWearable technology company Vuzix posts year-end net lossMarch 15, 2025 | rbj.netVuzix (NASDAQ:VUZI) Announces Earnings ResultsMarch 14, 2025 | marketbeat.comVuzix' Subsidiary Moviynt Secures Smart Glasses Deployment Commitment from Airbus HelicoptersMarch 14, 2025 | prnewswire.comVuzix Corporation: Vuzix Reports 4Q and Full Year 2024 Financial ResultsMarch 14, 2025 | finanznachrichten.deQ4 2024 Vuzix Corp Earnings CallMarch 14, 2025 | finance.yahoo.comVuzix (VUZI) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | finance.yahoo.comVuzix reports Q4 EPS (16c) vs. (32c) last yearMarch 14, 2025 | markets.businessinsider.comVuzix Corporation (VUZI) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comVuzix Reports 4Q and Full Year 2024 Financial ResultsMarch 13, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVUZI, GOVX, and CRDL Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$0.96 +0.06 (+6.81%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$0.94 -0.01 (-1.25%) As of 04/11/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.GeoVax Labs NASDAQ:GOVX$1.02 +0.07 (+7.31%) As of 04/11/2025 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Vuzix NASDAQ:VUZI$1.67 -0.02 (-1.18%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$1.69 +0.02 (+1.20%) As of 04/11/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vuzix Corporation designs, manufactures, and markets smart glasses and augmented reality (AR) technologies and products for the enterprise, medical, defense, and consumer markets. The company's products include head-mounted smart personal display and wearable computing devices that offer users a portable viewing experience, provide solutions for mobility, wearable displays, and augmented reality, as well as original equipment manufacturer waveguide optical components and display engines. It also provides certified ERP SaaS logistics solution to support hand-held mobile phones and scanners used in logistics, warehousing, and manufacturing applications. It holds approximately 375 patents and patents pending and various IP licenses in the fields of optics, head-mounted displays, and augmented reality Video Eyewear field. It sells its products through resellers, distributors, direct to commercial customers, and online stores, as well as various Vuzix operated web stores in North America, Europe, the Asia-Pacific, and internationally. The company was formerly known as Icuiti Corporation and changed its name to Vuzix Corporation in September 2007. Vuzix Corporation was incorporated in 1997 and is headquartered in West Henrietta, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review — 04/07 - 04/11 JPMorgan is a Buy, if You Can Handle The Volatility Rocket Lab Stock: Weathering the Storm, Time for a Comeback? United States Steel's Crash: An Unmissable Buying Opportunity Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves Is Archer Aviation’s Stock Price Dip a Gift? Marvell Gets Tariff Lifeline But Expect More Volatility Snowflake Boosts Growth by Doubling Down on AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
